Journal of the National Cancer Institute · 2026
Walking dose associated with lower cancer-related fatigue among patients with breast cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mattick Lindsey J, Li Chin-Shang, Lin Po-Ju, Peppone Luke J, Magnuson Allison, Melnik Marianne, Gross Howard, Onitilo Adedayo A, Kleckner Amber S, Mustian Karen M, Janelsins Michelle C
Аннотация
BACKGROUND: Cancer-related fatigue is a debilitating side effect among patients with cancer. Exercise is recommended to manage cancer-related fatigue; however, clinical guidelines lack specificity on modality, intensity, and duration. This study aimed to determine the optimal doses of walking to mitigate cancer-related fatigue.
METHODS: In a nationwide, prospective cohort study of patients with stage I-IIIC breast cancer, we assessed walking volume (metabolic equivalent task [MET] hours per week) via Aerobics Center Longitudinal Study Physical Activity measure and cancer-related fatigue via Multidimensional Fatigue Symptom Inventory at prechemotherapy (T1), 1 month postchemotherapy (T2), and 6 months postchemotherapy (T3). A receiver operating characteristic curve analysis identified a cut point for walking volume needed for a clinically meaningful cancer-related fatigue reduction from T1 to T2 (-4.5 points Multidimensional Fatigue Symptom Inventory score). Linear mixed models controlling for age, body mass index, and other modes of moderate-vigorous intensity exercise characterized cancer-related fatigue at each time point.
RESULTS: Among 577 participants (mean age = 53.4 years; 76% stage I-II), higher walking volume was associated with lower general, emotional, physical, overall cancer-related fatigue, and higher vigor postchemotherapy (T2; all P < .05). Those who walked at least 4.3 MET hours per week, equivalent to walking 88-172 minutes at a low-intensity pace (<2.5 mph) or 43-83 minutes at a moderate-intensity pace (2.6-4.5 mph) at pre, during, and postchemotherapy demonstrated statistically significantly lower cancer-related fatigue at postchemotherapy (T2) compared with those who walked less than 4.3 MET hours per week (P < .05).
CONCLUSIONS: Our data indicate that higher walking volume was associated with lower cancer-related fatigue, and a minimum walking volume of 88-172 minutes at a low-intensity pace or 43-83 minutes of moderate-intensity pace may attenuate cancer-related fatigue following chemotherapy.
METHODS: In a nationwide, prospective cohort study of patients with stage I-IIIC breast cancer, we assessed walking volume (metabolic equivalent task [MET] hours per week) via Aerobics Center Longitudinal Study Physical Activity measure and cancer-related fatigue via Multidimensional Fatigue Symptom Inventory at prechemotherapy (T1), 1 month postchemotherapy (T2), and 6 months postchemotherapy (T3). A receiver operating characteristic curve analysis identified a cut point for walking volume needed for a clinically meaningful cancer-related fatigue reduction from T1 to T2 (-4.5 points Multidimensional Fatigue Symptom Inventory score). Linear mixed models controlling for age, body mass index, and other modes of moderate-vigorous intensity exercise characterized cancer-related fatigue at each time point.
RESULTS: Among 577 participants (mean age = 53.4 years; 76% stage I-II), higher walking volume was associated with lower general, emotional, physical, overall cancer-related fatigue, and higher vigor postchemotherapy (T2; all P < .05). Those who walked at least 4.3 MET hours per week, equivalent to walking 88-172 minutes at a low-intensity pace (<2.5 mph) or 43-83 minutes at a moderate-intensity pace (2.6-4.5 mph) at pre, during, and postchemotherapy demonstrated statistically significantly lower cancer-related fatigue at postchemotherapy (T2) compared with those who walked less than 4.3 MET hours per week (P < .05).
CONCLUSIONS: Our data indicate that higher walking volume was associated with lower cancer-related fatigue, and a minimum walking volume of 88-172 minutes at a low-intensity pace or 43-83 minutes of moderate-intensity pace may attenuate cancer-related fatigue following chemotherapy.